Literature DB >> 21794781

Sildenafil in severe peripheral ischemia induced by terlipressin. A case report.

David D Bañuelos Ramírez1, Silvia Sánchez Alonso, María Magdalena Ramírez Palma.   

Abstract

A female patient in the sixth decade of life developed renal failure secondary to gastrointestinal bleeding, which was non-responsive to conventional therapy. She was treated with terlipressin iv; showing improvement but developing, over the next few days, ischemia and necrosis of the toes in the lower extremities, simulating necrotizing vasculitis, without response to regular management. An alternative therapy, oral sildenafil 50mg BID, was used, with a rapid reversal of the clinical picture. The vasodilator action of sildenafil is useful in cases of ischemia induced by some drugs. The objective this report is to warm about the utility of sildenafil in some potentially severe cases, like the one above.
Copyright © 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21794781     DOI: 10.1016/j.reuma.2010.05.005

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  4 in total

1.  A rare and threatening complication in a cirrhotic patient.

Authors:  Joana Carvalho E Branco; Vera Anapaz; Liliana Santos; Jorge Reis
Journal:  Intern Emerg Med       Date:  2018-04-26       Impact factor: 3.397

2.  A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease.

Authors:  Heon Ju Lee; Myung Jin Oh
Journal:  Clin Mol Hepatol       Date:  2013-06-27

3.  Terlipressin-induced Peripheral Ischemic Gangrene in a Diabetic Patient.

Authors:  Phulen Sarma; Gaurav Muktesh; Narender Dhaka; Rakesh Ruhela; Abhishek Mishra; Rahul Singh; Saroj K Sinha; Bikash Medhi; Rakesh Kochhar
Journal:  J Pharmacol Pharmacother       Date:  2017 Jul-Sep

4.  Terlipressin-induced ischaemic skin necrosis.

Authors:  Anand V Kulkarni; Pramod Kumar; Nagaraj P Rao; Nageshwar Reddy
Journal:  BMJ Case Rep       Date:  2020-01-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.